CN118359609A - 杂环化合物，其制备方法和用途 - Google Patents
杂环化合物，其制备方法和用途 Download PDFInfo
- Publication number
- CN118359609A CN118359609A CN202410157715.1A CN202410157715A CN118359609A CN 118359609 A CN118359609 A CN 118359609A CN 202410157715 A CN202410157715 A CN 202410157715A CN 118359609 A CN118359609 A CN 118359609A
- Authority
- CN
- China
- Prior art keywords
- optionally substituted
- alkyl
- alkynyl
- alkenyl
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/282—Platinum compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (8)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2019087772 | 2019-05-21 | ||
| CNPCT/CN2019/087772 | 2019-05-21 | ||
| CNPCT/CN2019/095947 | 2019-07-15 | ||
| CN2019095947 | 2019-07-15 | ||
| CN2019123223 | 2019-12-05 | ||
| CNPCT/CN2019/123223 | 2019-12-05 | ||
| CN202080004519.0A CN112585129B (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
| PCT/CN2020/091274 WO2020233592A1 (en) | 2019-05-21 | 2020-05-20 | Heterocyclic compounds, preparation methods and uses thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080004519.0A Division CN112585129B (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN118359609A true CN118359609A (zh) | 2024-07-19 |
Family
ID=73459463
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410157715.1A Pending CN118359609A (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
| CN202210122162.7A Pending CN114437065A (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
| CN202080004519.0A Active CN112585129B (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210122162.7A Pending CN114437065A (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
| CN202080004519.0A Active CN112585129B (zh) | 2019-05-21 | 2020-05-20 | 杂环化合物，其制备方法和用途 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11091481B2 (enExample) |
| EP (1) | EP3972967A4 (enExample) |
| JP (2) | JP7100210B2 (enExample) |
| KR (1) | KR102944305B1 (enExample) |
| CN (3) | CN118359609A (enExample) |
| AU (1) | AU2020279287B2 (enExample) |
| BR (1) | BR112021023136A2 (enExample) |
| CA (1) | CA3139348A1 (enExample) |
| IL (1) | IL288104B2 (enExample) |
| MX (1) | MX2021014096A (enExample) |
| WO (1) | WO2020233592A1 (enExample) |
| ZA (1) | ZA202110422B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019217307A1 (en) | 2018-05-07 | 2019-11-14 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| AU2019338207B2 (en) | 2018-09-10 | 2025-01-02 | Mirati Therapeutics, Inc. | Combination therapies |
| CA3112043A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| US12208099B2 (en) | 2018-09-10 | 2025-01-28 | Mirati Therapeutics, Inc. | Combination therapies |
| SMT202500028T1 (it) | 2018-09-10 | 2025-03-12 | Mirati Therapeutics Inc | Terapie combinate |
| WO2020085504A1 (ja) | 2018-10-26 | 2020-04-30 | 大鵬薬品工業株式会社 | 光照射ザンドマイヤー反応を用いたクロロアゾールカルボキシレート誘導体の製造方法 |
| US12377101B2 (en) | 2018-12-05 | 2025-08-05 | Mirati Therapeutics, Inc. | Combination therapies |
| WO2020146613A1 (en) | 2019-01-10 | 2020-07-16 | Mirati Therapeutics, Inc. | Kras g12c inhibitors |
| CN114615981B (zh) | 2019-08-29 | 2024-04-12 | 米拉蒂治疗股份有限公司 | Kras g12d抑制剂 |
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| CN114761012B (zh) | 2019-09-24 | 2025-03-21 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| MD4051678T2 (en) | 2019-10-28 | 2026-07-31 | Merck Sharp & Dohme Llc | Small molecule inhibitors of the KRAS G12C mutant |
| WO2021085653A1 (en) | 2019-10-31 | 2021-05-06 | Taiho Pharmaceutical Co., Ltd. | 4-aminobut-2-enamide derivatives and salts thereof |
| EP4067343A4 (en) | 2019-11-29 | 2024-01-03 | Taiho Pharmaceutical Co., Ltd. | NEW PHENOLIC COMPOUND OR SALT THEREOF |
| WO2021120045A1 (en) | 2019-12-18 | 2021-06-24 | InventisBio Co., Ltd. | Heterocyclic compounds, preparation methods and uses thereof |
| PH12022551513A1 (en) | 2019-12-20 | 2023-04-24 | Mirati Therapeutics Inc | Sos1 inhibitors |
| EP4092026A4 (en) * | 2020-01-13 | 2024-03-06 | Suzhou Zelgen Biopharmaceutical Co., Ltd. | ARYL OR HETEROARYL PYRIDONE OR PYRIMIDINE DERIVATIVES, PRODUCTION METHOD AND USE THEREOF |
| CN114671866A (zh) * | 2020-12-25 | 2022-06-28 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN113105448A (zh) * | 2020-01-13 | 2021-07-13 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN112159405B (zh) * | 2020-02-04 | 2021-09-14 | 广州必贝特医药技术有限公司 | 吡啶并嘧啶酮类化合物及其应用 |
| CN114901663B (zh) * | 2020-03-02 | 2024-07-02 | 上海喆邺生物科技有限公司 | 一类芳香杂环类化合物及其在药物中的应用 |
| WO2021215544A1 (en) | 2020-04-24 | 2021-10-28 | Taiho Pharmaceutical Co., Ltd. | Kras g12d protein inhibitors |
| US12702658B2 (en) | 2020-04-24 | 2026-08-11 | Taiho Pharmaceutical Co., Ltd. | Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C |
| WO2021249563A1 (zh) * | 2020-06-12 | 2021-12-16 | 苏州泽璟生物制药股份有限公司 | 芳基或杂芳基并吡啶酮或嘧啶酮类衍生物及其制备方法和应用 |
| CN115916194A (zh) | 2020-06-18 | 2023-04-04 | 锐新医药公司 | 用于延迟、预防和治疗针对ras抑制剂的获得性抗性的方法 |
| US12655160B2 (en) | 2020-08-04 | 2026-06-16 | Mirati Therapeutics, Inc. | KRAS G12D inhibitors |
| CN114075195B (zh) * | 2020-08-21 | 2026-04-28 | 广东东阳光药业股份有限公司 | 嘧啶酮衍生物及其在药物中的应用 |
| EP4208261A1 (en) | 2020-09-03 | 2023-07-12 | Revolution Medicines, Inc. | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| EP4210833A4 (en) | 2020-09-11 | 2024-09-11 | Mirati Therapeutics, Inc. | CRYSTALLINE FORMS OF A KRAS G12C INHIBITOR |
| EP4216951B1 (en) | 2020-09-22 | 2026-04-01 | Mirati Therapeutics, Inc. | Kras g12d inhibitors |
| WO2022066805A1 (en) | 2020-09-23 | 2022-03-31 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022109487A1 (en) | 2020-11-23 | 2022-05-27 | Merck Sharp & Dohme Corp. | Spirocyclic-substituted 6,7-dihydro-pyrano[2,3-d]pyrimidine inhibitors of kras g12c mutant |
| CN116390919B (zh) * | 2020-11-24 | 2025-12-23 | 杭州多域生物技术有限公司 | 一种芳香化合物、其制备方法及应用 |
| JP2023551006A (ja) * | 2020-11-26 | 2023-12-06 | 上▲海▼翰森生物医▲薬▼科技有限公司 | 窒素含有複素環誘導体の塩、結晶、並びにその調製方法、及び使用 |
| EP4262807A4 (en) | 2020-12-15 | 2025-04-23 | Mirati Therapeutics, Inc. | Azachinazoline pan-KRAS inhibitors |
| WO2022133038A1 (en) | 2020-12-16 | 2022-06-23 | Mirati Therapeutics, Inc. | Tetrahydropyridopyrimidine pan-kras inhibitors |
| US20230107642A1 (en) | 2020-12-18 | 2023-04-06 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| JP2023554476A (ja) * | 2020-12-21 | 2023-12-27 | アビスコ セラピューティクス カンパニー リミテッド | 大環状ｋ－ｒａｓ ｇ１２ｃ阻害剤、その製造方法および使用 |
| US12697337B2 (en) | 2021-03-11 | 2026-08-04 | InventisBio Co., Ltd. | Solid dispersions |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| EP4378478A4 (en) | 2021-07-27 | 2025-11-12 | Toray Industries | MEDICINE FOR THE TREATMENT AND/OR PREVENTION OF CANCER |
| US20240374571A1 (en) | 2021-09-01 | 2024-11-14 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| CA3244999A1 (en) | 2022-03-31 | 2025-06-13 | Eisai R&D Management Co., Ltd. | Pharmaceutical composition for treating tumors |
| EP4511128A1 (en) | 2022-04-20 | 2025-02-26 | Kumquat Biosciences Inc. | Macrocyclic heterocycles and uses thereof |
| CN117462553A (zh) * | 2022-07-20 | 2024-01-30 | 益方生物科技(上海)股份有限公司 | 药物组合产品以及组合疗法 |
| US20260137665A1 (en) | 2022-10-11 | 2026-05-21 | Aadi Bioscience, Inc. | Combination therapies for the treatment of cancer |
| CN121487738A (zh) | 2023-03-30 | 2026-02-06 | 锐新医药公司 | 诱导ras gtp水解的组合物和其用途 |
| KR20250166103A (ko) | 2023-04-06 | 2025-11-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 종양 치료용 약제학적 조성물 |
| KR20260019479A (ko) | 2023-05-04 | 2026-02-10 | 레볼루션 메디슨즈, 인크. | Ras 관련 질환 또는 장애를 위한 병용 요법 |
| CN121889155A (zh) | 2023-08-07 | 2026-04-17 | 锐新医药公司 | 用于治疗ras蛋白相关疾病或病症的rmc-6291 |
| KR20260104082A (ko) | 2023-09-29 | 2026-07-03 | 디3 바이오 (우씨) 컴퍼니, 리미티드 | 암의 치료에 사용하기 위한 wx-001 또는 그의 유도체와 kras g12c 억제제의 조합물 |
| AU2024360465A1 (en) | 2023-10-12 | 2026-04-09 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| KR20260096846A (ko) | 2023-10-20 | 2026-06-24 | 머크 샤프 앤드 돔 엘엘씨 | Kras 단백질의 소분자 억제제 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025242126A1 (zh) * | 2024-05-22 | 2025-11-27 | 上海正大天晴医药科技开发有限公司 | 一种药物组合及其应用 |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026080377A1 (en) * | 2024-10-07 | 2026-04-16 | Theras, Inc. | Treatment methods with krasg12c inhibition |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| WO2026106912A1 (en) | 2024-11-12 | 2026-05-21 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026112260A1 (en) | 2024-11-21 | 2026-05-28 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026122764A2 (en) | 2024-12-06 | 2026-06-11 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026128688A2 (en) | 2024-12-13 | 2026-06-18 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026161839A1 (en) | 2025-01-27 | 2026-07-30 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CR20190338A (es) | 2016-12-22 | 2019-09-09 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso |
| CN108658972A (zh) | 2017-03-28 | 2018-10-16 | 中国海洋大学 | 一种取代内酰胺类化合物及其制备方法和用途 |
| UA127968C2 (uk) | 2017-05-22 | 2024-02-28 | Емджен Інк. | Інгібітори g12c kras і способи їх застосування |
| US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| MX2020010836A (es) | 2018-05-04 | 2021-01-08 | Amgen Inc | Inhibidores de kras g12c y métodos para su uso. |
| JP7369719B2 (ja) * | 2018-06-12 | 2023-10-26 | アムジエン・インコーポレーテツド | ＫＲａｓ Ｇ１２Ｃ阻害剤及びそれを使用する方法 |
| WO2020097537A2 (en) | 2018-11-09 | 2020-05-14 | Genentech, Inc. | Fused ring compounds |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN110256421A (zh) | 2019-06-26 | 2019-09-20 | 微境生物医药科技(上海)有限公司 | Kras-g12c抑制剂 |
| CN111377918B (zh) | 2019-11-29 | 2021-03-02 | 苏州信诺维医药科技有限公司 | 一种kras抑制剂化合物 |
| CN111205286B (zh) | 2020-01-13 | 2022-12-13 | 中科苏州药物研究院 | 作为kras g12c突变蛋白抑制剂的腈甲基哌嗪类衍生物及其应用 |
-
2020
- 2020-05-20 BR BR112021023136A patent/BR112021023136A2/pt unknown
- 2020-05-20 MX MX2021014096A patent/MX2021014096A/es unknown
- 2020-05-20 CN CN202410157715.1A patent/CN118359609A/zh active Pending
- 2020-05-20 CN CN202210122162.7A patent/CN114437065A/zh active Pending
- 2020-05-20 CA CA3139348A patent/CA3139348A1/en active Pending
- 2020-05-20 CN CN202080004519.0A patent/CN112585129B/zh active Active
- 2020-05-20 KR KR1020217041335A patent/KR102944305B1/ko active Active
- 2020-05-20 WO PCT/CN2020/091274 patent/WO2020233592A1/en not_active Ceased
- 2020-05-20 JP JP2021569009A patent/JP7100210B2/ja active Active
- 2020-05-20 EP EP20810834.0A patent/EP3972967A4/en active Pending
- 2020-05-20 AU AU2020279287A patent/AU2020279287B2/en active Active
-
2021
- 2021-02-10 US US17/172,988 patent/US11091481B2/en active Active
- 2021-07-01 US US17/365,503 patent/US12110289B2/en active Active
- 2021-11-14 IL IL288104A patent/IL288104B2/en unknown
- 2021-12-14 ZA ZA2021/10422A patent/ZA202110422B/en unknown
-
2022
- 2022-06-30 JP JP2022105508A patent/JP7679338B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2020279287B2 (en) | 2025-11-27 |
| CA3139348A1 (en) | 2020-11-26 |
| JP2022130631A (ja) | 2022-09-06 |
| EP3972967A1 (en) | 2022-03-30 |
| CN112585129A (zh) | 2021-03-30 |
| US11091481B2 (en) | 2021-08-17 |
| IL288104A (en) | 2022-01-01 |
| WO2020233592A1 (en) | 2020-11-26 |
| CN114437065A (zh) | 2022-05-06 |
| EP3972967A4 (en) | 2023-07-12 |
| US12110289B2 (en) | 2024-10-08 |
| KR20220010542A (ko) | 2022-01-25 |
| US20210355125A1 (en) | 2021-11-18 |
| BR112021023136A2 (pt) | 2022-01-04 |
| AU2020279287A1 (en) | 2021-12-16 |
| MX2021014096A (es) | 2022-02-11 |
| IL288104B1 (en) | 2026-04-01 |
| US20210198255A1 (en) | 2021-07-01 |
| IL288104B2 (en) | 2026-08-01 |
| CN112585129B (zh) | 2022-03-01 |
| JP7679338B2 (ja) | 2025-05-19 |
| JP7100210B2 (ja) | 2022-07-12 |
| ZA202110422B (en) | 2024-03-27 |
| KR102944305B1 (ko) | 2026-03-25 |
| JP2022525247A (ja) | 2022-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7679338B2 (ja) | 複素環化合物、その製造方法および用途 | |
| JP7644023B2 (ja) | ホスファチジルイノシトール３－キナーゼ阻害剤 | |
| IL293962A (en) | Mutant kras protein inhibitors | |
| CA2900748C (en) | Novel pyrimidine and pyridine compounds and their usage | |
| CN112739690A (zh) | 用作smarca2拮抗剂的吡啶-2-酮化合物 | |
| TW201706270A (zh) | 作為吲哚胺２，３-二加氧酶和／或色氨酸２，３-二加氧酶抑制劑之新穎之５或８-取代之咪唑並［１，５－ａ］吡啶 | |
| JP7383112B2 (ja) | アルキン誘導体およびその調製方法と用途 | |
| KR20130116358A (ko) | Pi3 키나아제 억제제로서 헤테로사이클릭 화합물 | |
| AU2011344270A1 (en) | Substituted 6,6-fused nitrogenous heterocyclic compounds and uses thereof | |
| CN111683662B (zh) | 取代嘧啶类化合物及其药物组合物和治疗方法 | |
| CN105503827A (zh) | Egfr抑制剂及其制备方法和用途 | |
| WO2020221209A1 (zh) | 一种cd73抑制剂，其制备方法和应用 | |
| JP2022514363A (ja) | Ｃ末端ｓｒｃキナーゼ阻害剤 | |
| CN116490188A (zh) | 含氮杂环类衍生物的盐、晶型及其制备方法和应用 | |
| CN119384420A (zh) | 新型par-2抑制剂 | |
| WO2023109751A1 (zh) | 嘧啶或吡啶类衍生物及其医药用途 | |
| TWI894448B (zh) | Ctla-4小分子降解劑及其應用 | |
| RU2828748C2 (ru) | Гетероциклические соединения, способы их получения и применения | |
| HK40041256A (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| HK40041256B (en) | Heterocyclic compounds, preparation methods and uses thereof | |
| CN113583020B (zh) | 一种jak2抑制剂及应用 | |
| HK40121672A (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| WO2026080226A1 (en) | Tricyclic derivatives, compositions and methods thereof | |
| HK40074266B (en) | Heteroaryl heterocyclic compounds and uses thereof | |
| HK40052933A (en) | Cd73 inhibitor, preparation method therefor and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20240719 Assignee: CHIA TAI TIANQING PHARMACEUTICAL GROUP Co.,Ltd. Assignor: Yifang Biotechnology (Shanghai) Co.,Ltd. Contract record no.: X2024990000495 Denomination of invention: Heterocyclic compounds, their preparation methods and applications License type: Exclusive License Record date: 20241029 |
|
| EE01 | Entry into force of recordation of patent licensing contract |